Get the Stockscreener App
5.33
1.33%
0.07
After Hours:
5.43
0.10
+1.88%
Savara Inc stock is traded at $5.33, with a volume of 1.29M.
It is up +1.33% in the last 24 hours and up +5.96% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.26
Open:
$5.37
24h Volume:
1.29M
Relative Volume:
0.82
Market Cap:
$1.09B
Revenue:
-
Net Income/Loss:
$-129.48M
P/E Ratio:
-9.5451
EPS:
-0.5584
Net Cash Flow:
$-106.97M
1W Performance:
+5.34%
1M Performance:
+5.96%
6M Performance:
-19.36%
1Y Performance:
+141.18%
1-Day Range:
$5.315
$5.525
1-Week Range:
$4.73
$5.525
52-Week Range:
$1.98
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.33 | 1.08B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com UK
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role By Investing.com - Investing.com Australia
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role - Investing.com Australia
Savara Announces Chief Financial And Administrative Officer Transition - TradingView
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO - Stock Titan
Savara Announces Chief Financial and Administrative Officer Transition - The Joplin Globe
Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 - marketscreener.com
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns - Yahoo Finance
SVRA News | SAVARA INC (NASDAQ:SVRA) - ChartMill
SVRA: All proposals, including director elections and plan amendments, were approved - TradingView
Oppenheimer Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Savara Reports Phase 3 Biomarker Gains for Rare Lung Disease - MyChesCo
SVRA Q1 2026 Earnings: Narrowing Loss and Operational ProgressRevenue Estimate Trend - newsline.com
Savara Reports Long-Term Phase 3 Data Supporting Molgramostim Durability - MyChesCo
Savara Reports Phase 3 Data Showing Exercise Gains in Rare Lung Disease Trial - MyChesCo
Savara Inc. (SVRA) Q1 2026 Earnings: EPS Miss Reflects Investment Phase as Pipeline AdvancesGeographic Revenue Trends - newsline.com
SVRA Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressAnalyst Coverage Count - The Legal Advocate
SVRA Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Revision Downgrade - newsline.com
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Finance
Savara Inc stock (US80633A1025): Jefferies conference appearance keeps rare-disease biotech in focus - AD HOC NEWS
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Pipeline DevelopmentAnalyst Coverage Count - thelegaladvocate.com
Rare lung disease biotech Savara heads to Jefferies investor conference - Stock Titan
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The Joplin Globe
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA) - Seeking Alpha
Savara Advances MOLBREEVI Toward FDA Decision as Loss Widens - MyChesCo
SVRA Q1 2026 Earnings: Wider Loss Amid Continued Pipeline DevelopmentEarnings Momentum Score - newsline.com
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Development - thelegaladvocate.com
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA) - simplywall.st
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates Pipeline CostsGuidance Update - thelegaladvocate.com
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Savara Inc. (SVRA) Faces Modest Pullback as Shares Test Support Levels Near $5.00Sector Sentiment - The Legal Advocate
Savara Inc. (SVRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com South Africa
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Savara Inc Stock (SVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
Feb 16 '26 |
Option Exercise |
1.76 |
1,807 |
3,180 |
302,644 |
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):